Discover
MLTX
MoonLake Immunotherapeutics
16.43
4 x 16.40
1 x 16.45
bid
ask
-
0.90
5.22%
01:30 PM
timesize
| Ytd | 24.62% | |
| 1y | -69.23% |
15.93
day range
17.48
5.95
52 week range
62.75
| Open | 17.23 | Prev Close | 17.33 | Low | 15.93 | High | 17.48 | Mkt Cap | 1.38B |
| Vol | 2.20M | Avg Vol | 1.13M | EPS | -3.87 | P/E | -4.25 | Forward P/E | -5.41 |
| Beta | 1.06 | Short Ratio | 4.07 | Inst. Own | 78.87% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 19.02 | 200-d Avg | 16.42 | 1yr Est | 28.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-17 | 2026-09 | -0.87 | N/A | N/A | N/A |
| 2026-08-10 | 2026-06 | -0.92 | -0.84 | 0.08 | 8.48% |
| 2026-05-11 | 2026-03 | -0.91 | -0.98 | -0.07 | -7.69% |
| 2026-02-25 | 2025-12 | -0.92 | -0.92 | N/A | N/A |
| 2025-11-05 | 2025-09 | -0.89 | -1.1 | -0.21 | -23.60% |
| 2025-08-05 | 2025-06 | -0.73 | -0.87 | -0.14 | -19.18% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-07-20 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-07-01 | Leerink Partners | Upgrade | Outperform | Outperform |
| 2026-06-09 | BTIG | Upgrade | Buy | Buy |
| 2026-06-08 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-05-12 | Needham | Upgrade | Buy | Buy |
| 2026-05-11 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-21 | BODENSTEDT MATTHIAS | Chief Financial Officer | 1.12M | Sale |
| 2026-03-30 | BVF PARTNERS L P | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2025-09-29 | CHEN BIHUA X. | Former | 0.00 | Sale |
| 2025-07-02 | MOUKHEIBIR CATHERINE | Director | 0.00 | Conversion of Exercise of derivative security |
| 2026-07-26 | REICH KRISTIAN | Officer | 0.00 | Sale |
| 2026-07-09 | SANTOS DA SILVA JORGE | Chief Executive Officer | 2.77M | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | BVF Inc. | 16.00M | 292.18M | 21.74% |
| 2026-03-30 | Deep Track Capital, Lp | 6.41M | 117.03M | 8.71% |
| 2026-03-30 | Cormorant Asset Management, LP | 4.48M | 81.81M | 6.09% |
| 2026-03-30 | Janus Henderson Group PLC | 3.45M | 63.03M | 4.69% |
| 2026-03-30 | Shaw D.E. & Co., Inc. | 2.39M | 43.65M | 3.25% |
| 2026-03-30 | MPM Bioimpact LLC | 1.81M | 33.07M | 2.46% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | T. Rowe Price Health Sciences Fund, Inc. | 887.03K | 16.20M | 1.20% |
| 2026-05-30 | BlackRock Funds-BlackRock Health Sciences Opportunities Portfolio | 161.39K | 2.95M | 0.22% |
| 2026-06-29 | Fidelity Select Portfolios-Select Biotechnology Portfolio | 143.56K | 2.62M | 0.20% |
| 2026-03-30 | JNL Series Trust-JNL MULTI-MANAGER SMALL CAP VALUE FUND | 109.45K | 2.00M | 0.15% |
| 2026-05-30 | VANGUARD WORLD FUND-Vanguard Health Care Index Fund | 94.92K | 1.73M | 0.13% |
| 2026-03-30 | Delaware Group Equity Funds IV-Nomura Healthcare Fund | 80.00K | 1.46M | 0.11% |